Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients

Korean Journal of Pediatrics

Volumn 53, Issue 12, 2010, Pages 1000-1005

  Kim, Dae I L ^a   Im, Mi Sun ^a   Choi, Jin Hyoung ^a   Lee, Jina ^a   Choi, Eun Hwa ^a   Lee, Hoan Jong ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Child; Drug monitoring; Vancomycin

Indexed keywords

EID: 79951804452     PISSN: 17381061     EISSN: 20927258     Source Type: Journal    
DOI: 10.3345/kjp.2010.53.12.1000     Document Type: Article

References (29)

1. Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin associated nephrotoxicity: grave concern or death by character assassination? Am J Med 2010;123:182.e1-e7.
2. Kaplan SL, Hulten KG, Gonzalez BE, Hammerman WA, Lamberth L, Versalovic J, et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005;40: 1785-1791.
3. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46:S360-S367.
4. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, et al. Vancomycin MIC plus heteroresistance and outcome of methicillinresistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009;47:1640-1644.
5. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007;45:S191-S195.
6. Hermsen ED, Hanson M, Sankaranarayanan J, Stoner JA, Florescu MC, Rupp ME. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin Drug Saf 2010;9:9-14.
7. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 14th ed. Hudson, OH:Lexi-Comp, 2007: 1596-8.
8. Schaad UB, McCracken GH Jr, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980;96:119-26.
9. Patanwala AE, Norris CJ, Nix DE, Kopp BJ, Erstad BL. Vancomycin dosing for pneumonia in critically ill trauma patients. J Trauma 2009; 67:802-4.
10. Geraci JE. Vancomycin. Mayo Clin Proc 1977;52:631-4.
11. Ambrose P, Winter ME. Vancomycin. Basic Clinical Pharmacokinetics. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2004:451-76.
12. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
13. Pillai SK, Wennersten C, Venkataraman L, Eliopoulos GM, Moellering RC, Karchmer AW. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Clin Infect Dis 2009;49:1169-74.
14. Levine DP. Vancomycin: a history. Clin Infect Dis 2006;42:S5-12.
15. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009;28:398-402.
16. Cunha BA. Vancomycin. Med Clin North Am 1995;79:817-31.
17. Cunha BA. Vancomycin revisited: A reappraisal of clinical use. Crit Care Clin 2008;24:393-420.
18. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
19. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infection. Clin Pharmacokinet 2004;43:925-42.
20. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycinintermediate Staphylococcus aureus. Clin Infect Dis 2004;38:448-51.
21. Sakoulas G, Gold HS, Cohen RA, Venkataraman L, Moellering RC, Eliopoulos GM. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006;57:699-704.
22. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcome for serious infections caused by methicillinresistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004;38:521-8.
23. Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J 1995;14:667-73.
24. Glover ML, Cole E, Wolfsdorf J. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function. J Crit Care 2000;15:1-4.
25. Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000;45:329-35.
26. Nivoche Y, Contrepois A, Cremieux AC, Carbon C. Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. J Pharmacol Exp Ther 1982;222:237-40.
27. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit. Clin Pharmacokinet 2001;40:833-68.
28. Jeffres MN, Isakow W, Doherty JA, McKinnon PS, Ritchie DJ, Micek ST, et al. Predictor of mortality for methicillin resistant Staphylococcus aureus healthcare-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006;130:947-55.
29. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006;166:2138-44.